ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

12 يناير 2026 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

08 ديسمبر 2025 16:00:00 بحسب Nasdaq GlobeNewswire

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

17 نوفمبر 2025 08:01:11 بحسب Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

13 نوفمبر 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 نوفمبر 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

04 نوفمبر 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

30 أكتوبر 2025 09:15:00 بحسب Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

30 أكتوبر 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

28 أكتوبر 2025 08:30:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conferences

27 أكتوبر 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

24 أكتوبر 2025 08:00:00 بحسب Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

06 أكتوبر 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 أكتوبر 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

29 سبتمبر 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

17 سبتمبر 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

16 سبتمبر 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 سبتمبر 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

03 سبتمبر 2025 11:43:39 بحسب Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conferences

19 أغسطس 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 أغسطس 2025 16:00:00 بحسب Nasdaq GlobeNewswire